Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft

Catheterization and Cardiovascular Interventions

Volumn 68, Issue 4, 2006, Pages 567-573

  Jung, Jae Hun ^a   Min, Pil Ki ^b   Kim, Jong Youn ^c   Park, Sungha ^d   Choi, Eui Young ^d   Ko, Young Guk ^d   Choi, Donghoon ^d   Jang, Yangsoo ^d   Shim, Won Heum ^d   Cho, Seung Yun ^d  

^a Hallym University Medical Center   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Coronary artery disease; Kidney transplantation; Renal dialysis; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; CILOSTAZOL; CLOPIDOGREL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; CYCLOSPORINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSTHESIS FAILURE; RETROSPECTIVE STUDIES; STENTS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33749654828     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20799     Document Type: Article

References (50)

1. Gruentzig AR, King SB III, Schlumpf MS, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty: The early Zurich experience. N Engl J Med 1987;316:1127-1132.
2. Nicod P, Scherrer U. Explosive growth of coronary angioplasty: Success story of a less than perfect procedure. Circulation 1993; 87:1749-1751.
3. Serruys PW, de Jaegere P, Kiemeneij F, et al., on behalf of Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
4. Fischman DL, Leon MB, Baim DS, et al., on behalf of Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
5. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA 2000;284:1828-1836.
6. Jonasson L, Holm J, Hansson GK. Cyclosporin inhibits smooth muscle proliferation in the vascular response to injury. Proc Natl Acad Sci USA 1988;85:2303-2306.
7. Voisard R, Seitzer U, Baur R, et al. A prescreening system for potential antiproliferative agents: Implications for local treatment strategies of postangioplasty restenosis. Int J Cardiol 1995;51: 15-28.
8. Kahn J, Rutherford B, McConahay D, et al. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J 1990;119:484-489.
9. Rhnehart A, Herzog C, Collins A, et al. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995;25:281-290.
10. Schoebel FC, Gradaus F, Ivens K, et al. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: A case-control study using quantitative coronary angiography. Heart 1997;78:337-342.
11. Azar RR, Prpic R, Ho KK, et al. Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol 2000;86:485-489.
12. Arruda JA, Costa MA, Brito FS Jr, Tedesco H, Barbosa AH, Ribeiro EP, Pestana JO, Lima VC. Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients. Am J Cardiol 2003;91:1363-1365.
13. Zoja C, Furci L, Ghilardi F, et al. Cyclosporin-induced endothelial cell injury. Lab Invest 1986;55:455-462.
14. Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131-138.
15. Jonasson L, Holm J, Skalli O, et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985;76:125-131.
16. Hansson GK, Jonasson L, Holm J, et al. Class II MHC antigen expression in the atherosclerotic plaque: Smooth muscle cells express HLA-DR, HLA-DQ and the invariant γ-chain. Clin Exp Immunol 1986;64:261-268.
17. Jonasson L, Holm J, Hansson GK. Smooth muscle cells express Ia antigens during arterial response to injury. Lab Invest 1987; 58:310-315.
18. Osada M, Takeda S, Ogawa R, et al. T lymphocyte activation and restenosis after percutaneous transluminal coronary angioplasty. J Interferon Cytokine Res 2001;21:219-221.
19. Ferns G, Reidy M, Ross R. Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol 1990;137:403-413.
20. Leszczynski D, Zhao Y, Yeagley TJ, et al. Direct and endothelial cell-mediated effect of cyclosporin A on the proliferation of rat smooth muscle cells in vitro. Am J Pathol 1993;142:149-155.
21. Mohacsi PJ, Tuller D, Hulliger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-492.
22. Tavares P, Martinez-Salgado C, Eleno N, et al. Effect of cyclosporin A on rat smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998;31:46-49.
23. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995;59:655-661.
24. Andersen HØ, Hansen BF, Holm P, et al. Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation. Arterioscler Thromb Vasc Biol 1999;19:1687-1694.
25. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-975.
26. Wieneke H, Dirsch O, Sawitowski T, et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 2003;60:399-407.
27. Bartorelli AL, Trabattoni D, Fabbiocchi F, et al. Synergy of passive coating and targeted drug delivery: The tacrolimus-eluting Janus CarboStent. J Interv Cardiol 2003;16:499-505.
28. Voisard R, Seitzer U, Baur R, et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994;43:257-267.
29. Jarvelainen H, Halme T, Ronnemaa T. Effect of cortisol on the proliferation and protein synthesis of human aortic smooth muscle cells in culture. Acta Med Scand Suppl 1982;660:114-122.
30. Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999;138:60-63.
31. Fraser-Smith EB, Rosete JD, Schatzman RC. Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J Pharmacol Exp Ther 1995;275:1204-1208.
32. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11:1735-1743.
33. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-589.
34. Moses JW, Leon MB, Popma JJ, et al., on behalf of SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
35. Stone GW, Ellis SG, Cox DA, et al., on behalf of TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350: 221-231.
36. Stamler JS, Vaughan DE, Rudd MA, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988; 62:1268-1272.
37. Copstein LA, Zelmanovitz T, Goncalves LF, et al. Posttransplant diabetes mellitus in cyclosporine-treated renal allograft patients: A case-control study. Transplant Proc 2004;36:882,883.
38. Malanuk RM, Nielsen CD, Thesis P, et al. Treatment of coronary artery disease in hemodialysis patients: PTCA vs. stent. Catheter Cardiovasc Interv 2001;54:459-463.
39. Hase H, Nakamura M, Joki N, et al. Independent predictors of restenosis after percutaneous coronary revascularization in haemodialysis patients. Nephrol Dial Transplant 2001;16:2372-2377.
40. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102: 2966-2972.
41. Le Feuvre C, Dambrin G, Helft G, et al. Comparison of clinical outcome following coronary stenting or balloon angioplasty in dialysis versus non-dialysis patients. Am J Cardiol 2000;85: 1365-1368.
42. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30: 1428-1436.
43. Gruberg L, Dangas G, Mehran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002;55:66-72.
44. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99: 2434-2439.
45. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-223.
46. Hoffmann R, Mintz GS, Mehran R, et al. Tissue proliferation within and surrounding Palmaz-Schatz stents is dependent on the aggressiveness of stent implantation technique. Am J Cardiol 1999;83:1170-1174.
47. Viener A, Aviram M, Better OS, et al. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 1986;43:139-143.
48. Sabo RS, Bartoli F, Apitz-Castro R. In vivo platelet hyperactivity, another risk factor for patients under continuous ambulatory peritoneal dialysis. Nephron 1988;49:228-230.
49. Notohamiprodjo M, Andrassy K, Bommer J, et al. Dialysis membranes and the coagulation system. Blood Purif 1986;4:130-141.
50. Rodriguez AE, Alemparte MR, Vigo CF, et al. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stem therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol 2003;15:581-584.